CompletedNCT03266757Updated Apr 5, 2019

Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma

An observational study in Pancreatic Adenocarcinoma, sponsored by Hellenic Society of Medical Oncology. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-05.

Sponsored by Hellenic Society of Medical Oncology · Observational

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 200
Ages: 18 Years and older
Sex: All

Study summary

Observational study of the Clinical Practice in patients with Borderline resectable or resectable or advanced pancreatic adenocarcinoma.

Conditions studied

Pancreatic Adenocarcinoma

Browse trials for

Adenocarcinoma 2,004

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

Public and Private Hospital Institutions

Inclusion criteria

Patients Age 18 or older with histologically confirmed ductal pancreatic adenocarcinoma as a primary tumor
Patients with ductal pancreatic adenocarcinoma (Borderline resectable or resectable or advanced)
Patients that are alive and under treatment or follow up
Signed informed consent (ICF)

Exclusion criteria

Exclusion Criteria:

Presence of other primary tumors
Pancreatic adenocarcinoma due to metastasis from other primary tumor(s)
Neuroendocrine or other pancreatic carcinoma other than ductal adenocarcinoma
Patients who refuse to provide informed consent

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 200 participants (actual)
Patient registry: No

What researchers measure

Primary outcomes

clinical practice-treatments
Time frame: 2 years

Secondary outcomes

progression Free Survival
Time frame: 2 years
Overall Survival
Time frame: 2 years

Study locations

No study locations are listed for this record.

Registry details

Key details

Study ID: NCT03266757
Lead sponsor: Hellenic Society of Medical Oncology
Responsible party: Sponsor
First posted: Aug 30, 2017
Start date: Feb 11, 2016
Primary completion: Feb 11, 2017
Completion: Feb 11, 2018
Last update: Apr 5, 2019

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Adenocarcinoma→

Other studies from this sponsor

Hellenic Society of Medical Oncology

Start the discussion